Modern Management of Chronic Myelogenous Leukemia (CML)

References

• Minot G R, Beeckman T E, Isaacs R. Chronic myelogenous leukemia: Patients' age incidence duration and benefit derived from irradiations. JAMA 1924; 82: 1489–1499
   Google Scholar
• Monfardini S, Gee T, Freid J, et al. Survival in chronic myelogenous leukemia: influence of treatment and extensive disease at diagnosis. Cancer 1973; 31: 492–501
   PubMed Web of Science ®Google Scholar
• Medical Research Council's working party for therapeutic trials in leukemia. Chronic granulocytic leukemia: comparison of radiotherapy and busulfan therapy. Br Med J 1968; 1: 201–208
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, McCredie K, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69(5)1280–1288
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group in Chronic Myeloid Leukemia: Results of prospective randomized trial of early splenectomy in chronic myelogenous leukemia. Cancer 1984; 54: 333–338
   PubMed Web of Science ®Google Scholar
• Singer J W, Adamson J W, Arlin Z A, et al. Chronic myelogenous leukemia in vitro studies of hematopoetic regulation in a patient undergoing intensive chemotherapy. J Clin Invest 1981; 67: 1593–1598
   PubMed Web of Science ®Google Scholar
• Golde D W, Bersch N L, Sparkes R, et al. Chromosomal mosaicism associated with prolonged remission in chronic myelogenous leukemia. Cancer 1976; 37: 1849–1852
   PubMed Web of Science ®Google Scholar
• Benjamin D, Djaldetti M, Mammon Z, et al. Prolonged busulfan induced remission in chronic myeloid leukemia. Acta Hematol 1979; 62: 119–120
   PubMed Web of Science ®Google Scholar
• Cunningham I, Gee T, Dowling M, et al. Results of treatment of Ph+ chronic myelogenous leukemia with an intensive treatment regimen (L5 protocol). Blood 1979; 53: 375
   PubMed Web of Science ®Google Scholar
• Goto T, Nishakori M, Arlin Z, et al. Growth characteristics of leukemia and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intense treatment. Blood 1987; 70(3)793–808
   Google Scholar
• Kantarjian H M, Vellekoop L, McCredie K, et al. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 1985; 3: 192–200
   PubMed Web of Science ®Google Scholar
• Oladipupo-Williams C K, Svet Moldavskaya I, Vilcek J, et al. Inhibitory effects of human leukocyte in fibroblast interferons in normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981; 38: 356–360
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. New Engl J Med 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Clarkson B. Chronic myelogenous leukemia is aggressive treatment indicated. J Clin Oncol 1985; 3(2)135–139
   PubMed Web of Science ®Google Scholar
• Thomas E D, Glift R, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163
   PubMed Web of Science ®Google Scholar
• Goldman J M, Apperly J F, Jones L, et al. Bone marrow transplantation for patients with chronic myelogenous leukemia. N Engl J Med 1986; 314: 202–207
   PubMed Web of Science ®Google Scholar
• McGlave P B, Arthur D, Haake R, et al. Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 1987; 5: 1033–1040
   PubMed Web of Science ®Google Scholar
• Cratwohl A, Gluckman E, Goldman J, et al. Effect of splenectomy before bone marrow transplantation on survival in chronic granulocytic leukemia. Lancet 1985; 2: 1290–1291
   PubMed Web of Science ®Google Scholar
• Prentice H G, Janossy G, Price-Jones L, et al. Depletion of T-lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukemic marrow transplant recipients. Lancet 1984; 1: 472
   PubMed Web of Science ®Google Scholar
• Mitsuyasu R, Champlin R, Gale R, et al. Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft versus host disease. Ann Intern Med 1986; 105: 20–26
   PubMed Web of Science ®Google Scholar
• Martin P, Hansen J, Buckner C D, et al. Effects of in vitro depletion of T cells in HLA identical allogeneic marrow grafts. Blood 1985; 66(3)664–672
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Shank B, Collins S, et al. Increased total body irradiation abrogates resistence to HLA matched marrow grafts depleted of T cells by lectin agglutination and E-rosette depletion (abstr). Exp Hematol 1985; 13: 406
   Web of Science ®Google Scholar
• Bozdech M, Sundel P, Trigg M E, et al. Transplantation of HLA haploidentical T cell depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985; 13: 1201–1210
   PubMed Web of Science ®Google Scholar
• Apperly J F, Jones L, Aruthur C, et al. Incidence of relapse after T cell depleted marrow transplant for chonic granulocytic leukemia in first chronic phase (abstr). Blood 1986; 68: 270a
   Google Scholar
• Mathe G, Ahmed J, Schwarzanberg C, et al. Adopted immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965; 25: 1525
   PubMed Web of Science ®Google Scholar
• Bearman S, Appelbaum F, Buckner C, et al. Toxicity associated with preparative regimens in patients undergoing bone marrow transplantation. Blood 1986; 68: 280a, (abstract)
   Google Scholar
• Ritz J, Takvorian T, Anderson K, et al. Prevention of graft versus host disease (GVHD) following allogeneic bone marrow transplantation by in vitro depletion of mature T-lymphocytes using anti-T-12 monoclonal antibody (abstr). Blood 1986; 68: 291a
   Google Scholar
• Dube I D, Kalousek D K, Coulombel L, et al. Cytogenetic studies of early myeloid progenitor compartments in Ph+ chronic myeloid leukemia: Part II long term culture reveals the persistence of Ph- progenitors in treated as well as newly dignosed patients. Blood 1984; 63: 1172–1177
   PubMed Web of Science ®Google Scholar
• Beatty P, Clift R, Miekelson E, et al. Marrow transplantation from related donors other than HLA identical siblings. N Engl J Med 1985; 313: 763–771
   Google Scholar
• McGlave P, Scott E, Ramsey N, et al. Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia. Blood 1987; 70(3)877–881
   PubMed Web of Science ®Google Scholar
• Marks S, Baltimore D, McCaffrey R, et al. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Eng J Med 1978; 298: 812–814
   PubMed Web of Science ®Google Scholar
• Jain K, Arlin Z, Mertelsmann R, et al. Philadelphia chromosome and terminal transferase positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation. J Clin Oncol 1983; 1: 609
   Google Scholar
• Vemant J P, Rodet M, Rochant H, et al. Successful allogeneic bone marrow transplantation after reversal to chronic phase of blast crisis in chronic myeloid leukemia. Am J Hematol 1981; 11: 205–207
   PubMed Web of Science ®Google Scholar
• McGlave P B, Arthur D C, Kim T, et al. Successful allogeneic bone marrow transplantation for patients in the accelerated phase of chronic granulocytic leukemia. Lancet 1982; ii: 625–627
   Google Scholar
• Coleman M, Silver R, Pajak T, et al. Combination chemotherapy for terminal phase chronic granulocytic leukemia. Cancer and leukemia group B studies. Blood 1980; 55: 29–36
   Google Scholar
• Vallejos C, Trujillo J, Cork A, et al. Blastic crisis in chronic granulocytic leukemia: experience in 39 patients. Cancer 1974; 34: 1806–1812
   PubMed Web of Science ®Google Scholar
• Hayes D M, Ellison R R, Glidwell O, et al. Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer Chemother Rep 1974; 4: 233–247
   Google Scholar
• Arlin A Z, Berman E, Jhanwar S, et al. Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. Cancer Chetno Pharmacol 1986; 17: 189–190
   PubMed Web of Science ®Google Scholar